Spurious drugs case: Kingpin’s travel to Turkiye exposes racket’s international links
The alleged mastermind of a counterfeit medicines operation, identified as Prashanth, repeatedly travelled to Turkiye to obtain genuine pharmaceutical labels that were later affixed to fake drugs, according to investigators. The finding, emerging from questioning by a Special Investigation Team (SIT) that currently has him in custody, points to an international supply chain supporting the racket and reveals sophisticated methods used to pass off spurious products as legitimate medicines.
How investigators say the scheme worked
Investigators believe Prashanth tapped intermediaries in Turkiye to procure original labels from a pharmaceutical company. These authentic labels, once brought into the network, were allegedly applied to counterfeit drugs. The relabelled products were then repackaged and circulated in the market as genuine medicines, significantly raising the risk of the fakes going undetected in routine checks.
In a further effort to avoid scrutiny, the SIT’s probe has indicated that the accused and his associates sometimes mixed counterfeit medicines with genuine stock before distribution. By diluting fake products with real ones, the network allegedly sought to reduce the likelihood of immediate detection while maintaining a steady flow of spurious supplies into the supply chain.
Travel pattern suggests wider international reach
According to sources familiar with the investigation, Prashanth travelled to Turkiye several times a year in connection with the procurement of the original labels. However, his Turkiye visa was reportedly cancelled on multiple occasions. Following these cancellations, he is suspected to have begun routing his movements through neighbouring countries to continue the operation.
Officials said the accused also travelled to several other countries during this period. He is understood to have been in Azerbaijan prior to his arrest, where he was “holed up,” according to sources. These movements, investigators say, underscore the cross-border nature of the network and the role of overseas intermediaries in enabling the alleged tampering and relabelling activities.
Key developments uncovered by the SIT
– Repeated travel to Turkiye allegedly to obtain genuine pharmaceutical labels through intermediaries.
– Alleged use of those labels on counterfeit products that were then repackaged and supplied as authentic medicines.
– Reported mixing of fake and original medicines to reduce the risk of detection in the distribution chain.
– Cancellation of the accused’s Turkiye visa on multiple occasions, prompting suspected travel to neighbouring countries.
– Stay in Azerbaijan before arrest, pointing to a broader international footprint for the operation.
Focus of the ongoing investigation
The SIT is now examining the international links that supported the alleged operation, including the identities and roles of intermediaries who facilitated access to original labels. Investigators are also reviewing the accused’s travel to various destinations to map the network’s routes and methods, and to determine how the genuine labels were sourced, transported and integrated into the counterfeiting pipeline.
Officials are seeking to pinpoint the stages at which counterfeit medicines were mixed with or substituted for genuine stock, and to identify potential gaps in the supply chain that allowed the repackaged products to circulate as authentic. The probe is expected to continue tracing the flow of materials and funds involved and to pursue leads in the countries frequented by the accused.
Why the revelations matter
While details about specific brands or batches allegedly targeted have not been disclosed, investigators say the use of original labels on counterfeit medicines significantly complicates detection. The approach not only masks telltale signs of forgery but also allows fake products to appear credible at first glance, especially when combined with repackaging and controlled mixing with genuine stock.
The SIT’s findings so far have highlighted the need to scrutinize sources of packaging materials and labels, and to account for how genuine components may be diverted or misused outside official channels. Officials indicated that the international dimension of the case would remain a central line of inquiry as they work to identify all parties involved.
What comes next
Authorities continue to question the accused and his associates as they build a clearer picture of the network’s structure and scale. The SIT is following up on overseas links, focusing on intermediaries who allegedly facilitated the procurement of authentic labels and any other materials that could have been used to bolster the appearance of legitimacy.
Further actions are expected to revolve around corroborating travel records, cross-border communication, and the chain of custody for both genuine and counterfeit products. Officials said the investigation remains active and is likely to widen as additional leads emerge from the analysis of seized materials and information gathered during interrogation.
Conclusion
The discovery of repeated international travel to source genuine pharmaceutical labels, along with evidence of mixing counterfeit and original medicines, has deepened concerns about the sophistication and reach of the alleged racket. With the accused in SIT custody and the probe expanding to examine overseas intermediaries and destinations, investigators say they are working to dismantle the broader network and prevent further circulation of spurious medicines in the market.
